标普和纳斯达克内在价值 联系我们

Becton, Dickinson and Company BDXB NYSE

NYSE • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
64/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Becton, Dickinson and Company (BDXB) 当前追踪市盈率 (P/E) 为 8.3. 追踪盈利收益率为 12.11%.

本页证实的标准:

  • VALUE (100/100, 通过) — 市盈率低于市场平均水平 (8.3); 盈利收益率超过债券收益率 (12.11%).
  • 追踪盈利收益率 12.11% — 超过典型债券收益率(约4.3%),使股票相对固定收益更具吸引力。

SharesGrow 综合评分: 64/100 其中 3/7 项标准通过。

SharesGrow 7-Criteria Score
64/100
SG Score
View full scorecard →
价值
100/100
Price-to-Earnings & upside
Proven by this page
~
未來
40/100
Analyst consensus
→ Forecast
过去
100/100
→ Income
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
护城河
73/100
→ Income
~
成长
40/100
→ Income
~
收入
45/100
→ Income

估值概览 — BDXB

估值倍数
P/E (TTM)8.3
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.63
EV/EBITDA0.0
每股数据
EPS (TTM)$5.83
每股账面价值$0.00
每股营收$76.06
每股自由现金流$0.00
收益率与内在价值
盈利收益率12.11%
股息收益率0.00%

EPS:实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year EPS(稀释) 营收 净利润 净利润率
2016 $4.49 $12.48B $976M 7.8%
2017 $4.60 $12.09B $1.1B 9.1%
2018 $1.18 $15.98B $311M 1.9%
2019 $3.94 $17.29B $1.22B 7.1%
2020 $2.72 $17.12B $874M 5.1%
2021 $6.85 $20.25B $2.09B 10.3%
2022 $5.88 $18.87B $1.78B 9.4%
2023 $4.94 $19.37B $1.48B 7.7%
2024 $5.86 $20.18B $1.71B 8.4%
2025 $5.83 $21.84B $1.68B 7.7%
联系我们
🎓
SharesGrow 学院
学习如何计算内在价值,发现被低估的股票。
每周在线课程
给我们留言